| Since the middle of 2003, Albatross-Software.com initiated a program whereby they donate a percentage of each sale to the Cystic Fibrosis Foundation (CFF), an organization with little overhead, allowing donations to reach the root cause. Researchers are making great strides toward a cure for cystic fibrosis, which affects approximately 30,000 children and adults in the United States. The Cystic Fibrosis Foundation is the most efficient voluntary health organization of its kind with 89 cents of every dollar raised being made available for investment in CF research, care and education programs. Nicole Zimmerman, of the CFF Orlando chapter explains, "the healthy percentage of sales that Albatross-Software.com has chosen to donate is warmly appreciated by the Cystic Fibrosis Foundation, and is a generous model that we would encourage, from a enterprise of any size. We have a saying at the CFF 'Adding Tomorrows Everyday' and donations like the ones from Albatross and others truly help the fight for a cure." To learn more about how to donate to this cause, in ways other than purchasing The Aviary software package, visit www.atross.com, or www.cff.org. Special thanks to Candice Nethercott for getting Albatross-Software.com involved in donations for the Cystic Fibrosis Foundation. | Sites to Visit |
The following articles are developments in the search for a cure to cystic fibrosis:
| Targeted
Genetics : Firm continues trial on cystic fibrosis
SEATTLE TIMES 6/24/04 -- Targeted Genetics, a Seattle biotech company, said yesterday it will keep enrolling patients in a midstage clinical trial for its cystic-fibrosis treatment, after an independent committe took an early peek at the trail and found it has a chance to succeed. Targeted Genetics had scheduled the interim trial analysis to give it guidance on whether or not to pull the plug on the trail -- its most developed program -- or to keep investing in it. The double-blind, placebo-controlled trial has enrolled at least 53 patients so far, and plans are to enroll 100 by year's end. Last year, the company reported detailed results of a smaller trial that showed the treatment was safe. Although effectiveness diminished over time, it showed statistically significant effectiveness at improving breathing ability after 30 days. |
Sites to Visit |